OncoSec Medical (NASDAQ:ONCS) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, BTIG Research decreased their target price on OncoSec Medical from $10.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, March 16th.

NASDAQ:ONCS opened at $0.86 on Wednesday. The firm has a market cap of $33.85 million, a PE ratio of -0.91 and a beta of 2.03. OncoSec Medical has a fifty-two week low of $0.67 and a fifty-two week high of $4.25. The business has a 50 day moving average price of $0.83 and a 200-day moving average price of $0.95.

OncoSec Medical (NASDAQ:ONCS – Get Rating) last announced its earnings results on Tuesday, June 14th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. As a group, equities research analysts forecast that OncoSec Medical will post -0.59 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC bought a new position in shares of OncoSec Medical during the third quarter valued at approximately $45,000. Salzhauer Michael raised its holdings in OncoSec Medical by 15.9% in the fourth quarter. Salzhauer Michael now owns 321,354 shares of the biotechnology company’s stock worth $308,000 after purchasing an additional 44,042 shares in the last quarter. Long Focus Capital Management LLC bought a new position in OncoSec Medical in the fourth quarter worth $66,000. Two Sigma Advisers LP raised its holdings in OncoSec Medical by 128.2% in the third quarter. Two Sigma Advisers LP now owns 361,401 shares of the biotechnology company’s stock worth $770,000 after purchasing an additional 203,010 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in OncoSec Medical by 653.7% in the first quarter. Bank of New York Mellon Corp now owns 386,074 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 334,849 shares in the last quarter. Institutional investors own 13.98% of the company’s stock.

About OncoSec Medical (Get Rating)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.

Featured Stories